Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) Short Interest Up 29.3% in August

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,061,697 shares, an increase of 29.3% from the August 15th total of 821,241 shares. Based on an average daily volume of 151,075 shares, the days-to-cover ratio is presently 7.0 days. Approximately 6.8% of the shares of the company are short sold.

Separately, HC Wainwright set a $6.00 target price on Ampliphi Biosciences and gave the stock a “buy” rating in a research report on Friday, August 10th.

A hedge fund recently bought a new stake in Ampliphi Biosciences stock. Sabby Management LLC purchased a new stake in shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 831,961 shares of the biotechnology company’s stock, valued at approximately $907,000. Sabby Management LLC owned about 5.05% of Ampliphi Biosciences at the end of the most recent reporting period.

Shares of APHB traded down $0.01 during midday trading on Friday, reaching $1.01. The stock had a trading volume of 109,739 shares, compared to its average volume of 335,178. Ampliphi Biosciences has a 12-month low of $0.76 and a 12-month high of $2.05.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. Ampliphi Biosciences had a negative return on equity of 31.85% and a negative net margin of 2,050.00%.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply